Curcumin and Piperine Combination for the Treatment of Patients with Non-alcoholic Fatty Liver Disease: A Double-Blind Randomized Placebo-Controlled Trial

Mirhafez, Seyed Reza; Dehabeh, Maryam; Hariri, Mitra; Farimani, Azam Rezaie; Movahedi, Ali; Naderan, Ronika Danesh; Jamialahmadi, Tannaz; Simental‐Mendía, Luis E.; Sahebkar, Amirhossein

doi:10.1007/978-3-030-73234-9_2

Cited by 21 publications

(21 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All eight trials were RCTs. Seven studies were conducted using a parallel design (Cicero et al, 2020; Mirhafez et al, 2021; Panahi et al, 2014a; Panahi et al, 2017b; Panahi et al, 2019; Saberi‐Karimian et al, 2020; Tabaee et al, 2021), and one had a cross‐over design (Mohammadi et al, 2013). Articles were published from 2012 through 2021.…”

Section: Resultsmentioning

confidence: 99%

“…For example, in a study by Cicero, TG and HDL cholesterol concentration improved significantly in NAFLD patients (Cicero et al, 2020). Moreover, a study by Mirhafez et al revealed TG concentration improvement in NAFLD patients (Mirhafez et al, 2021). These results show that the therapeutic effect of curcumin and piperine has some variations in terms of the type of disease, which might be due to different characteristics of the studied subjects.…”

Section: Discussionmentioning

confidence: 99%

“…The results of former studies about the impact of curcumin plus piperine supplements on lipid profiles in patients with MetS are equivocal. Although several investigators have suggested favorable effects from curcumin (Cicero et al, 2020; Panahi et al, 2017b; Panahi et al, 2019; Rahimnia, Panahi, Alishiri, Sharafi, & Sahebkar, 2015; Tabaee et al, 2021), other investigations have not detected any significant impact (Mirhafez et al, 2021; Mohammadi et al, 2013; Panahi, Khalili, Hosseini, Abbasinazari, & Sahebkar, 2014b; Saberi‐Karimian et al, 2020). Therefore, the present meta‐analysis of randomized controlled trials (RCTs) was performed to provide a more accurate and precise estimate of the effect of curcumin plus piperine on lipid profile in patients with MetS and associated disorders.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

A systematic review and meta‐analysis of randomized controlled trials investigating the effect of the curcumin and piperine combination on lipid profile in patients with metabolic syndrome and related disorders

Hosseini

Ghavidel

Panahi

et al. 2023

Phytotherapy Research

Self Cite

View full text Add to dashboard Cite

Metabolic syndrome is characterized by multiple metabolic disorders. Several studies indicated that curcumin plus piperine could affect lipids profiles in various diseases.The present meta-analysis aims to assess the effect of curcumin plus piperine on lipid profiles in patients with MetS and associated disorders using a systematic review and meta-analysis of randomized controlled trials. Trials were searched by several electronic databases up to May 2022. The Comprehensive Meta-Analysis (CMA) version3 software carried out this systematic review and meta-analysis. Random-effects model and the inverse variance method were used to conduct the meta-analysis. We evaluated the publication bias and heterogeneity of all eligible studies. In addition, subgroup analyses and sensitivity assessments were performed to assess potential sources of heterogeneity. The combined results by the random-effects model demonstrated that curcumin plus piperine significantly decreased total cholesterol and LDL-C in patients suffering from metabolic syndrome. In comparison, the results of the overall effect size did not show any significant change in triglyceride concentrations. Our results were robust in sensitivity analysis and were not dependent on the dose of curcumin, the dose of piperine, and the duration of treatment. Our results showed that co-administration of piperine and curcumin supplementation improves the lipid profile in metabolic syndrome. However, further long-term RCTs are required to ascertain their clinical benefit.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A systematic review and meta‐analysis of randomized controlled trials investigating the effect of the curcumin and piperine combination on lipid profile in patients with metabolic syndrome and related disorders

Hosseini

Ghavidel

Panahi

et al. 2023

Phytotherapy Research

Self Cite

View full text Add to dashboard Cite

show abstract

“…Sixteen RCTs 22 – 37 were included in the updated MA with the outcomes including AST (N = 15), ALT (N = 14), ALP (N = 6), GGT (N = 2), US grading (N = 9), liver stiffness (N = 2), platelet count (N = 2), FBS (N = 12), HbA1c (N = 3), BMI (N = 13), TC (N = 11), TG (N = 11), LDL-C (N = 11), HDL-C (N = 10), SBP (N = 5 ), DBP (N = 5), FIB4 (N = 1), NFS (N = 1), APRI (N = 1), and BARD (N = 1), see Fig. 1 .…”

Section: Resultsmentioning

confidence: 99%

“…Fitting follow-up time in the meta-regression did not improve I 2 . Subgroup analysis was performed by curcumin forms, i.e., whole compounds (N = 3) 22 , 24 , 35 , curcumin extracts (N = 1) 31 , and bioavailability-enhanced forms (N = 11) 23 , 25 , 27 – 30 , 32 – 34 , 36 , 37 . The AST-lowering effect was stronger across all bioavailability-enhanced forms [MD (95% CI) of −4.59 (−7.03, −2.15) units/L], but not significant for whole compounds [MD (95% CI) of −3.02 (−7.55, 1.52) units/L].…”

Section: Resultsmentioning

confidence: 99%

An updated meta-analysis of effects of curcumin on metabolic dysfunction-associated fatty liver disease based on available evidence from Iran and Thailand

Lukkunaprasit

Tansawet

Boonmanunt

et al. 2023

Sci Rep

View full text Add to dashboard Cite

Metabolic dysfunction-associated fatty liver disease (MAFLD) is a common cause of chronic liver disease and can progress to nonalcoholic steatohepatitis and cirrhosis. This study aims to summarize the evidence for the effects of curcumin on MAFLD progression. Studies were identified from Medline and Scopus databases until April 2022. Systematic reviews and meta-analyses (SRMA) and randomized controlled trials (RCT) were selected based on pre-specified criteria. Three reviewers independently extracted data and assessed quality of included studies. Of the 427 identified records, 6 SRMAs and 16 RCTs were included in the analysis. Very high overlap was observed among SRMAs with corrected covered area of 21.9%. From an updated meta-analysis, curcumin demonstrated significant improvement in aspartate and alanine aminotransferase with pooled mean difference [95% confidence interval (CI)] of −3.90 (−5.97, −1.82) and −5.61 (−9.37, −1.85) units/L, respectively. Resolution and improvement of hepatic steatosis was higher in curcumin than control group with pooled relative risk (95% CI) of 3.53 (2.01, 6.22) and 3.41 (1.36, 8.56), respectively. Curcumin supplementation also led to lower fasting blood sugar, body mass index, and total cholesterol. Further trials should be conducted to assess the effect of curcumin on liver histology, especially regarding non-invasive hepatic fibrosis and steatosis.

show abstract

Curcumin‐piperine co‐supplementation and human health: A comprehensive review of preclinical and clinical studies

Heidari

Bagherniya

Majeed

et al. 2023

Phytotherapy Research

Self Cite

View full text Add to dashboard Cite

Curcumin is extracted from the rhizomes Curcuma longa L. It is known for its anti‐inflammatory and anti‐oxidant activities. Despite its safety and potential for use against various diseases, curcumin's utility is restricted due to its low oral bioavailability. Co‐administration of curcumin along with piperine could potentially improve the bioavailability of curcumin. The present review aimed to provide an overview of the efficacy and safety of curcumin‐piperine co‐supplementation in human health. The findings of this comprehensive review show the beneficial effects of curcumin‐piperine in improving glycemic indices, lipid profile and antioxidant status in diabetes, improving the inflammatory status caused by obesity and metabolic syndrome, reducing oxidative stress and depression in chronic stress and neurological disorders, also improving chronic respiratory diseases, asthma and COVID‐19. Further high‐quality clinical trial studies are needed to firmly establish the clinical efficacy of the curcumin‐piperine supplement.

show abstract

Curcumin and Piperine Combination for the Treatment of Patients with Non-alcoholic Fatty Liver Disease: A Double-Blind Randomized Placebo-Controlled Trial

Cited by 21 publications

References 29 publications

A systematic review and meta‐analysis of randomized controlled trials investigating the effect of the curcumin and piperine combination on lipid profile in patients with metabolic syndrome and related disorders

A systematic review and meta‐analysis of randomized controlled trials investigating the effect of the curcumin and piperine combination on lipid profile in patients with metabolic syndrome and related disorders

An updated meta-analysis of effects of curcumin on metabolic dysfunction-associated fatty liver disease based on available evidence from Iran and Thailand

Curcumin‐piperine co‐supplementation and human health: A comprehensive review of preclinical and clinical studies

Contact Info

Product

Resources

About